Kornimate/medical-research-clean huggingface dataset:
ultrafiltration profiling and outcomes among individuals on maintenance hemodialysis

Conditions: End Stage Renal Disease

Summary: the rate of fluid removal (ultrafiltration, uf) during hemodialysis (hd) may contribute to cardiovascular morbidity and mortality among individuals receiving maintenance hd. more rapid uf rates are associated with higher morbidity and mortality. ultrafiltration profiling, the practice of varying uf rates to maximize fluid removal during periods of greatest hydration and plasma oncotic pressures, is one treatment modification that may reduce uf-related harm without necessitating reduction in interdialytic fluid intake or longer hd treatments. to date, uf profiling has not been adequately studied independent of sodium profiling. this study investigates the comparative effect of uf profiling versus non-profiled conventional hd on select cardiovascular and patient-reported outcomes. participants will complete two phases of uf profiling and two phases of conventional hd and will act as their own controls.


Eligibility criteria:
inclusion criteria: * uf rate \>10 ml/h/kg in \>30% of treatments in a 30-day screening period (require ≥6 outpatient hd treatments in this period) * age 18-85 years * ability to converse comfortably in english or spanish * receipt of in-center maintenance hd at carolina dialysis clinics in carrboro or siler city, north carolina * ≥90 days on hd * free of bloodstream infection during screening period * willingness to undergo all study testing * evidence of a signed and dated informed consent document exclusion criteria: * systolic bp unable to be measured by arm cuff * \>1 hospitalization during screening period * unstable angina per treating nephrologist * end-stage cirrhosis per treating nephrologist * new york heart association class iv heart failure per treating nephrologist * pregnant * more than 4 times per week hd * incarcerated * anticipated kidney transplant within 6 months per treating nephrologist * non-adherence to hd prescription (\>2 unexplained absences during screening period) * sodium profiling or uf profiling in standard hd prescription * decisionally challenged, unable to provide informed consent

Keywords: ultrafiltration profiling hemodialysis dialysis cardiovascular outcomes patient-reported outcomes crossover study design end stage renal disease ultrafiltration echocardiogram blood pressure hypotension symptoms
effect of cross-legged sitting among patients with unilateral hip developmental dysplasia

Conditions: Hip Developmental Dysplasia

Summary: one of the most common infant developmental diseases is hip dysplasia which is mostly seen among female' babies and leads to hip instability due to partial or full hip dislocation \[1\]. physical therapy's role plays a significant role in treating hip dysplasia by creating new walking habits as an adaptation way and compensation for the deformity \[3\]. focusing on the muscles that produce hip abduction force is a basic item of the hip dysplasia rehabilitation program \[4\]. cross-legged sitting position can be considered as a common and easy position that might enhance the range of motion of the lower limb joints \[5\]. while unilateral hip developmental dysplasia has been widely distributed among newborns, especially in the last few years, the role of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation programs on improving the temporospatial parameters, muscular electrical activity and foot pressure distributing is still not clear. therefore, this study aimed to analyze the effects of engaging the cross-legged sitting technique as a part of physical therapy and rehabilitation program among patients with uhdd by comparing the group who participated in rehabilitation program with cls to the other without. to understand the importance of including cross-legged sitting technique in physical therapy and rehabilitation program of unilateral hip developmental dysplasia (uhdd) to enhance the spatial and temporal measures, achieving a healthy distribution of foot pressure, increasing the electrical activity of lower limb muscles and improving the overall gait pattern. no risks at all. all instruments and techniques in this study are safe and used regularly without any hazards. the data will be stored and archived on a password-protected computer for safety and security purposes. after accomplishing the research and getting the outcomes, the results of the research may be published as an academic article in a peer-reviewed journal. in another word, no personal data will be published at all. taking part in the study and withdrawing at any time is completely voluntary with no need to give any reason.


Eligibility criteria:
inclusion criteria: * age group from 9 months to 10 years old * all participants suffer from unilateral hip developmental dysplasia (uhdd) * participants should be healthy in general exclusion criteria: any participant with a history of neurological disorders, lower extremities previous surgical intervention, lower limb deformities, flat feet or high body mass index will be excluded from this study

Keywords: rehabilitation gait foot pressure hip developmental dysplasia
de-ct in lung cancer proton therapy

Conditions: Non Small Cell Lung Cancer

Summary: dose distribution calculations for proton therapy are more accurate when based on de-ct than on se-ct. it is however unclear what the quantitative benefit of repeated de-ct calculations is for lung cancer patients.

in order to calculate the dose distribution of protons adequately, accurate estimations of the stopping power ratio (spr) medium to water, are required. using a conversion from single energy ct (se-ct) images results in an uncertainty in the spr of at least 3-4%. this uncertainty results in in the use of larger margins around the clinical target volume (ctv) and hence more dose to the organs at risk (oar). it also effects in the conservative use of beam directions, which are often sub-optimal, to avoid irradiating normal tissues. dual energy ct (de-ct) improves the accuracy of the spr and therefore the proton range estimation. an evaluation of the proton range for several tissues using se-ct and de-ct as input to monte carlo (mc) simulations showed on average improvements in range prediction from 0.1% to 2.1% when using dect instead of sect, but in several phantoms and also versus proton-ct, the errors on se-ct based proton stopping power ratios are reported to be more than 7 %. a limitation of these studies is that most of them were performed in phantoms. in the first clinical data set on five patients with base of skull tumours, it was reported that although the spr estimation was indeed better for de-ct than for se-ct, its clinical relevance was unclear. however, in the same study, phantom measurements showed a large uncertainty of the spr in the lung. this is due to the large heterogeneity of the lungs and the huge difference in the density of the lungs compared to the mediastinum, the tumour and the chest cavity. it is therefore important to study the spr differences of se-ct compared to de-ct in lung cancer patients and the impact on the dose distribution especially in the context of adaptive radiotherapy. as during the course of concurrent chemotherapy and radiotherapy, which is the standard treatment in the majority of stage iii lung cancer patients, important anatomical changes may occur, it is also of clinical relevance to determine the influence of repeated dose calculations on de-ct.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed locally advanced stage iiia or iii b (t0-4 n2-3m0) nsclc, or m1 oligometastatic disease according to 7th tnm classification. * scheduled to receive concurrent chemotherapy and radiotherapy to a dose of at least 60 gy, as decided at the multidisciplinary tumour board * able to give written informed consent * able to have adequate contraception in woman with child bearing potential exclusion criteria: * not able to give written informed consent * not able to comply with adequate contraception in woman with child bearing potential
clinical decision support tools to increase human papillomavirus (hpv) vaccination in adolescents in pharmacies

Conditions: Human Papillomavirus-Related Carcinoma

Summary: this clinical trial develops and tests how well a clinical decision support (cds) tool works to increase human papillomavirus (hpv) vaccination of children between the age of 9-17 (adolescents) in pharmacies. hpv vaccination rate in eligible adolescents remains low even though over 90% of the cancers in adults caused by hpv can be prevented by the hpv vaccine. the national vaccine advisory committee recommends hpv vaccinations to be given in pharmacies to increase access to vaccines, but pharmacy processes and lack of awareness of the service among parents impact the use of local pharmacies for hpv vaccinations. using a focus group may be an effective method to develop a cds tool and create a process that may be more convenient for parents to get their adolescent's vaccine at their local pharmacy. a cds tool may make it easier to obtain hpv vaccines, and as a result increase the adolescent hpv vaccination rate and reduce the incidence of cancer caused by hpv.

outline: participants are assigned to 1 of 3 groups. group i: staff participate in facilitated planning discussions to develop cds tools on study. (aim i) group ii: staff receives cds tools training and implements cds tools to facilitate hpv vaccination on study. (aim ii) group iii: parents complete survey post-intervention on study. (aim ii)

Eligibility criteria:
inclusion criteria: * aim i: \>= 18 years * aim i: pharmacy staff: employed at the partnering community pharmacies in washington state * aim i: scientific technologies corportation (stc)health staff: employed at stchealth * aim i: pioneerrx staff: employed at pioneerrx * aim ii: \>= 18 years * aim ii: parents: english speaking parent or guardian of at least one child, ages 9-17, living in washington state and obtained an hpv vaccination for their child at a participating pharmacy and have access to a telephone or computer with internet access. * aim ii: pharmacy staff: employed at community pharmacies recruited into the study located in washington state exclusion criteria: * pharmacy staff: floaters/per diem. those who object to having the focus group discussions audio recorded. those who object to participating in implementation evaluation surveys * stchealth staff: those who object to having the focus group discussions audio recorded * pioneerrx staff: those who object to having the focus group discussions audio recorded * parents: those who decline to provide feedback on their experiences with getting their children vaccinated at the pharmacy
size progression of macular degeneration after cataract surgery

Conditions: Age-Related Macular Degeneration

Summary: the purpose of this study was to find out if in patients with non-exudative age-related macular degeneration (amd), randomly assigned to cataract surgery, any amd size progression or progression to exudative amd could be detected 6 months after surgery.


Eligibility criteria:
inclusion criteria: * patients with cataract and non-exudative age-related macular degeneration exclusion criteria: * patients with retinal pathologies other than amd, exudative amd, progressive glaucoma, myopia \> 10 diopters, panretinal laser treatment, former cataract or vitreoretinal surgery, were excluded.

Keywords: amd cataract surgery size of amd influence of cataract surgery on amd size
safety and immunogenicity of quadrivalent influenza mrna vaccine mrt5407 in adult participants18 years of age and older

Conditions: Influenza Immunization

Summary: the purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (im) injection of up to 2 dose levels of quadrivalent influenza messenger ribonucleic acid (mrna) vaccine mrt5407 compared to an active control (qiv standard-dose (sd), qiv high-dose (hd) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (riv4)) in adults 18 years of age and older.

study duration is approximately 12 months.

Eligibility criteria:
inclusion criteria: * aged 18 years on the day of inclusion * a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * is of non-childbearing potential. to be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile or * is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration. exclusion criteria: participants are excluded from the study if any of the following criteria apply: * known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * previous history of myocarditis, pericarditis, and / or myopericarditis * self-reported thrombocytopenia, contraindicating intramuscular vaccination based on investigator's judgment * bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment * moderate or severe acute illness / infection (according to investigator's judgment) or febrile illness (temperature ≥ 38.0°c \[≥ 100.4°f\]) on the day of vaccination. a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided * self-reported or documented seropositivity for human immunodeficiency virus, hepatitis b virus, or hepatitis c virus * receipt of any mrna vaccine/product in the 2 months preceding study intervention administration note: the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
neoadjuvant versus adjuvant therapy in treating resectable thoracic esophageal cancer

Conditions: Esophageal Cancer

Summary: this is a prospective randomized phase ⅱ trial comparing preoperative chemoradiotherapy (paclitaxel and carboplatin) followed by surgery to surgery followed by postoperative chemoradiotherapy (paclitaxel and carboplatin) for esophageal cancer.

patient population: thoracic esophageal cancer able to tolerate tri-modality therapy; clinical stage t3-4, n0-1, m0 scheme: patients are randomized to 2 arms: arm a: paclitaxel/carboplatin and concurrent radiation (50.4gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles. arm b: surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4gy/28f), consolidate paclitaxel/carboplatin 2 cycles.

Eligibility criteria:
inclusion criteria: * histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (\> 20cm from the incisors) or gastroesophageal junction are included. * no distant metastases (m0). * patients will be stratified by stage (clinical n0 versus clinical n1). * patients with tumours within 3 cm distal spread into gastric cardia as detected by esophagogastroscopy. * resectable mediastinal nodes are eligible. * no prior chemotherapy for this malignancy. * no prior radiotherapy that would overlap the field(s) treated in this study. * patients with other malignancies are eligible only if \> 5 years without evidence of disease or completely resected or treated non-melanoma skin cancer. * age \> 18 years and able to tolerate tri-modality therapy at the discretion of the treating thoracic surgeon, medical and radiation oncologists. tumours must be resectable after assessment by the thoracic surgeon. exclusion criteria: * cancers of the cervical esophagus (\< 20 cm are excluded). * tumours that have \> 3 cm of spread into cardia of the stomach are considered gastric cancers and are ineligible. * patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy ) proven metastatic supraclavicular nodes are ineligible. * patients with biopsy proven metastatic celiac nodes are ineligible.

Keywords: esophageal cancer resectable neoadjuvant chemoradiotherapy adjuvant chemoradiotherapy
cause and importance of the age-dependent sarcopenia

Conditions: Sarcopenia

Summary: the goal of this cross-sectional study is to evaluate the difference in cytokine profiling approach and mitochondrial function between geriatric sarcopenic patients (group 1) and geriatric non-sarcopenic patients (group 2) and healthy (group 3) geriatric participants.

study participants (group 1\&2) are assessed during the hospital stay and age-matched controls (group 3) will be recruited through flyers. the investigators aim to isolate and cryopreserve peripheral blood mononuclear cells (pbmcs) from whole blood to perform functional assays on mitochondrial respiratory capacity and ros. furthermore, the investigators will investigate the association between biomarkers and frailty, quality of life, functional performance, fatigue and risk of depression. the investigators hypothesize that this profiling approach will allow the evaluation of the progression of age-dependent sarcopenia and uncover novel therapeutic targets.

Eligibility criteria:
inclusion criteria: * age between 60 and 85 years * informed written consent * normal cognitive status according to mini-mental state examination (mmse ≥ 24 points) * life expectancy of \> 3 months according to treating doctor * without implanted defibrillation * without acute sepsis * without neurodegenerative diseases, especially amyotrophic lateral sclerosis (als) and huntington exclusion criteria: * age \ 85 years * lack of informed written consent * low cognitive status according to mini-mental state examination (mmse \< 24 points) * life expectancy of \< 3 months according to treating doctor * implanted defibrillation * acute sepsis * neurodegenerative diseases, especially amyotrophic lateral sclerosis (als) and huntington

Keywords: sarcopenia geriatrics biomarker
effect of double fortification (iron and zinc) in synbiotic milk to under 5 years stunted children growth

Conditions: Stunting

Summary: the purpose of this study is to investigate the effects of double fortification (iron and zinc) in synbiotic milk (l.plantarum dad13 and fructooligosaccharides) on under 5 years stunted children growth, gut microbiota composition, blood zinc and hemoglobin level, and cognitive level.

this is a parallel, quadruple-blind, randomized controlled trial to determine the effects of double fortification (iron and zinc) in synbiotic milk (containing 7 billion cfu l.plantarum dad13 and 4 g fructooligosaccharides) on the gut microbiota composition, body height and weight, blood zinc and hemoglobin level, and cognitive level in under 5 years stunted children subjects. the duration of the study is 4 months, including a 2-week pre test and informed consent before randomization of subjects into treatment or control group, a 12-week intervention period, and a 2-week post test after the end of intervention. during the intervention period, subjects will be instructed to take 100 ml of fortified synbiotic milk or non-fortified synbiotic milk per day. they will also be asked to document consumed milk, any unusual symptoms or side effects of treatment. diet will be monitored via 24-h dietary recalls and sq-ffq before and after treatment respectively. changes in the gut microbiota composition will be determined by measuring bacterial population levels (bifidobacteria, lactobacillus, enterobacteria, prevotella, and bacteroides) in stool sampled collected at baseline and 12 weeks by qpcr. metabolic markers (calprotectin, hemoglobin, and zinc level) will be measured at baseline and 12-weeks in serum and plasma using biochemical and immuno-assay. changes in the cognitive level, height for age z-score collected at baseline and 12 weeks using bayley scales of infant development, 2nd edition .

Eligibility criteria:
inclusion criteria: * age between 2 year to 5 years * height per age z-score under -2 (stunting) * parents sign inform consent form exclusion criteria: * have congenital abnormality * lactose intolerant * use antibiotic for more than 2 weeks * consume micronutrient supplement (especially iron and zinc) in the last 3 months * diagnose with chronic diseases and infection that interfere metabolism (i.e. tuberculosis, hiv, autoimmune disease, diabetes mellitus type 1) * suffer marasmus and/or kwashiorkor * not willing to continue the intervention
safety and effectiveness of treating hiv-positive patients with an hiv vaccine (remune)

Conditions: HIV Infections

Summary: the purpose of this study is to see if giving hiv-positive patients an hiv vaccine plus anti-hiv drugs can help lower hiv levels in the blood (viral load).

at the time of study entry, all patients are receiving a haart regimen consisting of three drugs from at least two classes of antiretroviral drugs. upon entering the study, patients receive remune or ifa at weeks 0, 12, and 24. patients remain on study for 40 weeks. patients who have received three injections of remune or ifa and whose plasma hiv-1 rna level is less than 50 copies/ml at week 26 discontinue haart at week 28. (if the patient has a plasma hiv-1 rna level at or above 50 copies/ml at week 26, he/she must have a measurement below 50 copies/ml at week 27 to proceed with haart discontinuation at week 28. if by week 27 the patient does not have a plasma hiv-1 rna level below 50 copies/ml, the patient does not discontinue haart but remains on study and has study visits at weeks 34 and 40.) patients who discontinue haart have their plasma hiv-1 rna levels measured on the day haart is discontinued and at days 3, 5, 7, 10, 14, 21, 28, 35, and 42 after discontinuation. patients with a plasma hiv-1 rna level of at least 5,000 copies/ml at week 34 restart haart at that time. (patients whose plasma hiv-1 rna level reaches greater than or equal to 100,000 copies/ml on two occasions before week 34 have the option of restarting haart immediately.) patients whose plasma hiv-1 rna level is less than 5,000 copies/ml at week 34 do not restart haart unless their level increases to at least 5,000 copies/ml. patients who discontinue haart are monitored intensively for the duration of the study. patients have 27 visits if they stay on study until completion at week 40.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * are receiving an anti-hiv drug combination that contains three drugs from at least two classes of anti-hiv drugs (such as protease inhibitors). patients must have been receiving this drug combination for at least 6 months before study entry. before beginning this drug combination, patients must have taken either no anti-hiv drugs or only one or two nucleoside analogues (nrtis). * had a viral load between 5,000 and 100,000 copies/ml before beginning their current anti-hiv therapy. * have a viral load below 50 copies/ml while on their current anti-hiv therapy within 2 weeks before study entry. * have a cd4 count greater than 350 cells/mm3 at the time of study entry. * are at least 13 years old (consent of parent or guardian required if under 18).

Keywords: hiv-1 drug therapy, combination rna, viral anti-hiv agents viral load remune